Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer.

1. Hughes MP, Hardee ME, Cornelius LA, Hutchins LF, Becker JC, Gao L. Merkel cell carcinoma: epidemiology, target, and therapy. Curr Dermatol Rep 2014;3:46-53. 2. Nardi V, Song Y, Santamaria-Barria JA, et al. Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res 2012; 18:1227-36. 3. Shao Q, Byrum SD, Moreland LE, et al. A proteomic study of human merkel cell carcinoma. J Proteomics Bioinform 2013;6: 275-82. 4. Fruman DA, Cantley LC. Idelalisib — a PI3Kδ inhibitor for B-cell cancers. N Engl J Med 2014;370:1061-2. 5. Ali K, Soond DR, Piñeiro R, et al. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 2014;510:407-11.